AR and prostate cancer: Consistent with our targeted AR studies, 100 and 250 nmol/L NXP800 (in contrast to its inactive chemical control, CCT365248, at 250 nmol/L) substantially impacted AR signaling with de-enrichment of the Hallmark Androgen Response in VCaP (100 nmol/L, NES −1.87, FDR <0.001; 250 nmol/L, NES −1.60, FDR 0.0134), LNCaP95 (100 nmol/L, NES −1.53, FDR 0.0165; 250 nmol/L, NES −1.87, FDR 0.0012), and 22Rv1 (100 nmol/L, NES −2.29, FDR <0.001; 250 nmol/L, NES −1.88, FDR <0.001) prostate cancer cells (Fig. 3C–E; Supplementary Tables S7–S9).